Hit by trial setback, Aslan slashes staff and a study — hunkering down in wait for pivotal data
Two weeks after reporting the failure of a key Phase II study of their lead drug, Aslan Pharmaceuticals $ASLN is restructuring, slashing staff and shuttering a trial as they aim for a pivotal win.
Out the exit goes Bertil Lindmark, the chief medical officer, now headed back to Europe. The CMO is leaving with 30% of the staff as the biotech slashes its burn rate in half. In other staff moves Chih-Yi Hsieh, the VP Medical and GM Taiwan, will take the role of acting CMO while COO Mark McHale becomes head of R&D.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.